The research has had the participation of 1,256 people, of which 571 were women and 742 had a family history of type 2 diabetes.
The treatment with eldecalcitolan active analogue of vitamin Din the prevention of type 2 diabetes have a “beneficial effect“. This is explained by the main researcher of the study, Tetsuya Kawahara of the University of Occupational and Environmental Health of Japan, published in British Medical Journal. Research shows how “with a eldecalcitol dose of 0.75 micrograms a day shows a potential beneficial effect following adjusting for confounding factors.
Despite this initial benefit, according to Kawahara, “the results did not show a very significant reduction in incidence of diabetes and also failed to increase the rate of regression to the normoglucemia compared with placebo among patients with glucose intolerance who had a high risk of type 2 diabetes“. Therefore, the principal investigator assures that “this finding should be repeated in other populations before it can be fully appreciated. importance for public health“.
The research has had the participation of 1,256 people, of which 571 were women (45.5 percent) and 742 (59.1 percent) had family history of type 2 diabetes. Also, the mean age of the participants was 61.3 years. During a median follow-up of 2.9 years, 79 (12.5 percent) of 630 participants in the eldecalcitol group and 89 (14.2 percent) of 626 in the placebo group developed type 2 diabetes.
Researcher Kawahara details in the study that “regression to normoglycemia occurred in 145 (23.0 percent) of the 630 participants in the group of eldecalcitol and in 126 (20.1 percent) of the 626 in the placebo group.” And that, following adjusting for confounders using multivariate Cox polynomial regression analysis, “the vitamin D showed its beneficial effect Among the participants with the lowest level of basal insulin secretion“.
|
Sex, age and plasma glucose were “factors that affect the incidence of diabetes” |
During follow-up, bone mineral densities of the lumbar spine and neck of the femur and serum osteocalcin concentrations were significantly increased with eldecalcitol compared with placebo. Also, according to Kawahara, “no significant differences were seen in serious adverse events.”
What is the benefit of vitamin D in type 2 diabetes?
In this randomized, placebo-controlled trial, “the effect of eldecalcitol on the incidence of type 2 diabetes in people with glucose intolerance in japan. It was designed and overseen by the steering committee and approved by the institutional review boards of three participating centers.”
According to Kawahara, “sub-investigators from all three trial hospitals reported to the assignment center for registration and treatment assignment. Participants were assigned to one of the two treatment groups on a one-to-one basis using a central randomization method.
To continue with the trial, “a person in charge of the allocation center prepared a randomization list for each hospital separately by a stratified permuted block procedure before the entry of the first participant. The number of strata was eight according to gender (male, female), age (30-54 years, ≥55 years), and plasma glucose two hours following the 75-gram oral glucose tolerance test.”
The researchers considered that “these factors affect the incidence of diabetesSimilarly, the trial shows how ” “block sizes were six for five permutation cycles and four for the next five permutation cycles, with the last 17 participants allocated using two block sizes, i.e. a total of 417 participants per hospital.
Although it may contain statements, data or notes from health institutions or professionals, the information contained in Medical Writing is edited and prepared by journalists. We recommend the reader that any questions related to health be consulted with a health professional.
